Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) PT at $21.33

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $21.33.

Several equities analysts have weighed in on NRIX shares. Royal Bank of Canada lifted their price objective on shares of Nurix Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a research report on Thursday, April 11th. Needham & Company LLC reissued a “buy” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, April 9th. Robert W. Baird raised their price objective on Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research report on Thursday, April 11th. Morgan Stanley upped their target price on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Finally, Wells Fargo & Company lowered their price objective on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Friday, February 16th.

Nurix Therapeutics Stock Down 1.3 %

NASDAQ:NRIX opened at $13.98 on Monday. The stock has a fifty day simple moving average of $13.94 and a 200 day simple moving average of $10.11. The firm has a market capitalization of $687.12 million, a price-to-earnings ratio of -5.26 and a beta of 2.10. Nurix Therapeutics has a 1-year low of $4.22 and a 1-year high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Wednesday, April 10th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.04. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. The company had revenue of $16.59 million during the quarter, compared to analysts’ expectations of $14.58 million. Equities analysts predict that Nurix Therapeutics will post -3.15 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Houte Hans Van sold 3,499 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total transaction of $44,892.17. Following the completion of the sale, the chief financial officer now directly owns 68,333 shares of the company’s stock, valued at approximately $876,712.39. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 13,705 shares of company stock valued at $154,012 over the last three months. 9.80% of the stock is currently owned by insiders.

Institutional Trading of Nurix Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. ProShare Advisors LLC grew its position in Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after buying an additional 998 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Nurix Therapeutics by 75.6% during the first quarter. Russell Investments Group Ltd. now owns 53,542 shares of the company’s stock worth $787,000 after acquiring an additional 23,044 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Nurix Therapeutics by 27.3% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,904 shares of the company’s stock valued at $454,000 after purchasing an additional 6,628 shares in the last quarter. J.W. Cole Advisors Inc. acquired a new stake in shares of Nurix Therapeutics during the 1st quarter worth about $265,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Nurix Therapeutics by 67.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after purchasing an additional 3,793 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.